Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 10Completed 8Active not recruiting 4Terminated 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 34Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16thymoglobulin 14Granulocyte Colony-Stimulating Factor 14venetoclax 13Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × asciminib × Myeloid × Clear all
NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Sir Mortimer B. Davis - Jewish General Hospital

Phase 3 Terminated
8 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡